Pre-market hot trades in US stocks: AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B pre-market down 11.08%; Lumentum pre-market down 3.03%

Pre-market Hot Trades in US Stocks AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B, pre-market down 11.08%, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Lumentum pre-market down 3.03%. Based on recent key news: On May 15, Lumentum director Pamela Fletcher sold 3,155 shares of common stock, leading to market doubts about internal confidence in the company, putting pressure on the stock price. According to SEC filings, the transaction prices were $1,003.38 and $940.82 per share. Source: EDGAR On May 18, the advantages of optical communication technology in AI computing scenarios were widely discussed, with the market expecting significant technological breakthroughs in the next two to three years, driving related stocks up. Source: Science and Technology Innovation Board Daily On May 18, JP Morgan analysts raised growth expectations for the data communication market, believing that demand for optical modules will be stronger, benefiting suppliers like Lumentum. Source: Science and Technology Innovation Board Daily. The demand for optical communication technology is growing, and market expectations are optimistic. Top Gainers in Pre-market US Stocks Amesite pre-market up 200.03%. Based on recent key news: On May 19, Amesite secured a new enterprise client involving approximately 2,700 patients, marking its largest deployment to date and validating its corporate strategy. The client will deploy NurseMagic AI documentation to streamline workflows, integrating its electronic medical records and electronic access verification workflows. This deployment is expected to significantly reduce the administrative burden on each nurse by up to 16 hours per week. Amesite's stock price rose 250% upon the news release. On May 19, director George Parmer purchased 243,902 shares of Amesite common stock at $1.44 per share, increasing his holdings to 566,962 shares. Additionally, he received 243,902 A-1 series and A-2 series warrants with an exercise price of $1.44 per share. On May 19, CEO Ann Marie Sastry purchased 174,216 shares of common stock at $1.44 per share, increasing her direct holdings to 1,049,647 shares. She also purchased 174,216 A-1 series and A-2 series warrants with an exercise price of $1.44 per share. Amesite is shifting towards AI solutions to reduce cash consumption. InMed Pharmaceuticals pre-market up 154.15%. Based on recent key news: On May 19, InMed Pharmaceuticals announced that it has reached a definitive merger agreement with Mentari Therapeutics for an all-stock transaction. This merger will combine Mentari's migraine prevention therapy pipeline with InMed's public market infrastructure. After the merger, InMed shareholders are expected to own approximately 1.51% of the merged company, which is anticipated to have an equity value of about $421.4 million. This news drove InMed's stock price up 195% in pre-market trading. On May 19, InMed Pharmaceuticals released a press release detailing the contents and expected impact of the merger agreement. The merged company will trade under a new stock code on the NASDAQ capital market. This news further boosted market confidence, driving the stock price higher. On May 19, InMed Pharmaceuticals published original content on PR Newswire, confirming the details of the merger agreement and future outlook. This news has left investors optimistic about the company's future development, further driving the stock price up. The biotechnology industry has shown strong performance recently, with significant capital inflows. Rubico, up 125.43% in pre-market trading, has had no significant news recently. Trading is active, with clear capital flows. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation